Market Cap 454.79B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 25.84
Forward PE 18.62
Profit Margin 6.91%
Debt to Equity Ratio -11.02
Volume 7,258,100
Avg Vol 7,045,918
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 19%
Beta 0.30
Analysts Strong Sell
Price Target $265.79

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 1 at 6:23 AM
$SLS @wwmeinc is either an idiot or a short idiot liar. The IDMC UNBLINDED ACTUAL PHASE 3 MOS AND IMMUNE RESPONSE DATA FROM THE INTERIM ANALYSIS. SINCE THEN: SLS SHARE PRICE +1,000% Market Cap+1,200%, Cash on hand Up 1,100% Institutional Funds Up 800% Smart Money Knows Dr’s treating actual patients, know. $ABBV knows - VIALE-M VIALE-T VERONA Failed idiots like wwmeinc don’t have a clue.
0 · Reply
RayWashburn860
RayWashburn860 Aug. 1 at 5:10 AM
$ABBV AbbVie combines stable pharmaceutical cash flows with an attractive dividend profile. New immunology and neuroscience products are expected to offset declining Humira revenue over the coming years.
0 · Reply
BioTechHealthX
BioTechHealthX Aug. 1 at 3:55 AM
$ABBV Humira sales plunged nearly 39%, but AbbVie’s revenue and earnings continued climbing as Skyrizi and Rinvoq delivered blockbuster growth. Here is why ABBV stock’s comeback story is turning heads. https://biotechhealthx.com/biotech-news/is-abbvie-abbv-a-smart-dividend-stock-to-buy-now/
0 · Reply
Wstb100
Wstb100 Jul. 31 at 11:17 PM
$ABBV closed my short. Enough to eat for free at a Jimmy Buffet restaurant for a table of 9. Back to my long position.
0 · Reply
ItTakes2toContango
ItTakes2toContango Jul. 31 at 5:29 PM
$ABBV Sold at $260 before ER simply because I won’t hold anything through ER in this environment. Price seems to have stabilized at ~$250 and I have bought back my shares. Looking for $270 by next ER.
1 · Reply
DidYouReadThis
DidYouReadThis Jul. 31 at 4:40 PM
1 · Reply
katiemcdaniels96
katiemcdaniels96 Jul. 31 at 3:01 PM
$ABBV AbbVie Reports Second-Quarter 2026 Financial Results | AbbVie https://share.google/LHV4rygaQs8RTMpXG
0 · Reply
Quantumup
Quantumup Jul. 31 at 2:48 PM
BRiley🏁 $FDMT and said -- We are initiating coverage of retinal genetic medicines specialist 4D Molecular Therapeutics, Inc. (FDMT) with a Buy rating and a 12-month price target of $37/share. OCUL EYPT $RGNX - $ABBV $REGN $RHHBY SRZN KOD OTLK NVS Here's what else BRiley had to say in its initiation report: https://x.com/Quantumup1/status/2083203038202692017?s=20
0 · Reply
EarningsInsider
EarningsInsider Jul. 31 at 2:31 PM
https://www.marketbeat.com/earnings/reports/2026-7-31-abbvie-inc-stock/ $ABBV AbbVie Earnings Transcript
0 · Reply
Social_Idiot
Social_Idiot Jul. 31 at 1:26 PM
$ABBV Over performing and exceeding expectations and projections everywehere.... Makes me think that they're bad at projections.
0 · Reply
Latest News on ABBV
AbbVie says ‘quite pleased’ with Skyrizi momentum

2026-07-31T14:01:14.000Z - 16 hours ago

AbbVie says ‘quite pleased’ with Skyrizi momentum


AbbVie sees Q3 adjusted EPS $3.84-$3.88, consensus $3.84

2026-07-31T13:30:48.000Z - 17 hours ago

AbbVie sees Q3 adjusted EPS $3.84-$3.88, consensus $3.84


AbbVie sees FY26 adjusted gross margin ‘above 84% of sales’

2026-07-31T13:30:35.000Z - 17 hours ago

AbbVie sees FY26 adjusted gross margin ‘above 84% of sales’


AbbVie Earnings Call Transcript: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 17 hours ago

AbbVie Earnings Call Transcript: Q2 2026


AbbVie Earnings release: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 17 hours ago

AbbVie Earnings release: Q2 2026


AbbVie Lowers Outlook to Account for Acquisition as Profit Jumps

Jul 31, 2026, 8:36 AM EDT - 18 hours ago

AbbVie Lowers Outlook to Account for Acquisition as Profit Jumps


AbbVie reports Q2 adjusted EPS $3.65, consensus $3.61

2026-07-31T11:51:57.000Z - 19 hours ago

AbbVie reports Q2 adjusted EPS $3.65, consensus $3.61


AbbVie Reports Second-Quarter 2026 Financial Results

Jul 31, 2026, 7:47 AM EDT - 19 hours ago

AbbVie Reports Second-Quarter 2026 Financial Results


JUVÉDERM® Day Returns to U.S. on August 19

Jul 30, 2026, 8:00 AM EDT - 1 day ago

JUVÉDERM® Day Returns to U.S. on August 19


AbbVie announces Elahere availability in Singapore

2026-07-29T09:30:43.000Z - 2 days ago

AbbVie announces Elahere availability in Singapore


AbbVie announces European Commission approval for Rinvoq

2026-07-29T09:15:30.000Z - 2 days ago

AbbVie announces European Commission approval for Rinvoq


AbbVie price target raised to $300 from $275 at Barclays

2026-07-29T09:10:59.000Z - 2 days ago

AbbVie price target raised to $300 from $275 at Barclays


AbbVie price target raised to $282 from $273 at Canaccord

2026-07-22T10:40:12.000Z - 9 days ago

AbbVie price target raised to $282 from $273 at Canaccord


AbbVie price target raised to $260 from $230 at Citi

2026-07-15T10:21:06.000Z - 16 days ago

AbbVie price target raised to $260 from $230 at Citi


AbbVie price target raised to $260 from $230 at UBS

2026-07-13T16:30:09.000Z - 18 days ago

AbbVie price target raised to $260 from $230 at UBS


AbbVie price target raised to $300 from $258 at BMO Capital

2026-07-13T12:27:09.000Z - 18 days ago

AbbVie price target raised to $300 from $258 at BMO Capital


AbbVie to Host Second-Quarter 2026 Earnings Conference Call

Jun 26, 2026, 8:00 AM EDT - 5 weeks ago

AbbVie to Host Second-Quarter 2026 Earnings Conference Call


AbbVie's $11 Billion Immunology Bet

Jun 24, 2026, 12:51 PM EDT - 5 weeks ago

AbbVie's $11 Billion Immunology Bet

APGE


AbbVie to Buy Apogee Therapeutics for $10.9 Billion

Jun 22, 2026, 10:15 AM EDT - 5 weeks ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

APGE


AbbVie Transcript: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 5 weeks ago

AbbVie Transcript: M&A announcement


AbbVie Slides: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 5 weeks ago

AbbVie Slides: M&A announcement


AbbVie Press release: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 5 weeks ago

AbbVie Press release: M&A announcement


AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

Jun 22, 2026, 7:42 AM EDT - 5 weeks ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

APGE


AbbVie strikes $10.9 billion deal for Apogee Therapeutics

Jun 22, 2026, 7:04 AM EDT - 5 weeks ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

APGE


AbbVie Declares Quarterly Dividend

Jun 18, 2026, 4:05 PM EDT - 6 weeks ago

AbbVie Declares Quarterly Dividend


US FDA approves AbbVie's rare blood cancer drug

May 27, 2026, 3:33 PM EDT - 2 months ago

US FDA approves AbbVie's rare blood cancer drug


AbbVie Transcript: AGM 2026

May 8, 2026, 10:00 AM EDT - 3 months ago

AbbVie Transcript: AGM 2026


55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 1 at 6:23 AM
$SLS @wwmeinc is either an idiot or a short idiot liar. The IDMC UNBLINDED ACTUAL PHASE 3 MOS AND IMMUNE RESPONSE DATA FROM THE INTERIM ANALYSIS. SINCE THEN: SLS SHARE PRICE +1,000% Market Cap+1,200%, Cash on hand Up 1,100% Institutional Funds Up 800% Smart Money Knows Dr’s treating actual patients, know. $ABBV knows - VIALE-M VIALE-T VERONA Failed idiots like wwmeinc don’t have a clue.
0 · Reply
RayWashburn860
RayWashburn860 Aug. 1 at 5:10 AM
$ABBV AbbVie combines stable pharmaceutical cash flows with an attractive dividend profile. New immunology and neuroscience products are expected to offset declining Humira revenue over the coming years.
0 · Reply
BioTechHealthX
BioTechHealthX Aug. 1 at 3:55 AM
$ABBV Humira sales plunged nearly 39%, but AbbVie’s revenue and earnings continued climbing as Skyrizi and Rinvoq delivered blockbuster growth. Here is why ABBV stock’s comeback story is turning heads. https://biotechhealthx.com/biotech-news/is-abbvie-abbv-a-smart-dividend-stock-to-buy-now/
0 · Reply
Wstb100
Wstb100 Jul. 31 at 11:17 PM
$ABBV closed my short. Enough to eat for free at a Jimmy Buffet restaurant for a table of 9. Back to my long position.
0 · Reply
ItTakes2toContango
ItTakes2toContango Jul. 31 at 5:29 PM
$ABBV Sold at $260 before ER simply because I won’t hold anything through ER in this environment. Price seems to have stabilized at ~$250 and I have bought back my shares. Looking for $270 by next ER.
1 · Reply
DidYouReadThis
DidYouReadThis Jul. 31 at 4:40 PM
1 · Reply
katiemcdaniels96
katiemcdaniels96 Jul. 31 at 3:01 PM
$ABBV AbbVie Reports Second-Quarter 2026 Financial Results | AbbVie https://share.google/LHV4rygaQs8RTMpXG
0 · Reply
Quantumup
Quantumup Jul. 31 at 2:48 PM
BRiley🏁 $FDMT and said -- We are initiating coverage of retinal genetic medicines specialist 4D Molecular Therapeutics, Inc. (FDMT) with a Buy rating and a 12-month price target of $37/share. OCUL EYPT $RGNX - $ABBV $REGN $RHHBY SRZN KOD OTLK NVS Here's what else BRiley had to say in its initiation report: https://x.com/Quantumup1/status/2083203038202692017?s=20
0 · Reply
EarningsInsider
EarningsInsider Jul. 31 at 2:31 PM
https://www.marketbeat.com/earnings/reports/2026-7-31-abbvie-inc-stock/ $ABBV AbbVie Earnings Transcript
0 · Reply
Social_Idiot
Social_Idiot Jul. 31 at 1:26 PM
$ABBV Over performing and exceeding expectations and projections everywehere.... Makes me think that they're bad at projections.
0 · Reply
msgetzoff
msgetzoff Jul. 31 at 1:22 PM
$ABBV ....blowout numbers and we're down (+)$10 ?? Forget the nonsensical reason of the Apogee acquisition & sales declines from Humira. Humira is old news & already baked in. As for Apogee, this is their business model. Pretty sure they know what 2do.
0 · Reply
profit_guru
profit_guru Jul. 31 at 1:19 PM
$ABBV - competition to skyrizi from $JNJ is big red flag for the high multiple going forward…near term 230..,imo
0 · Reply
crtlabz
crtlabz Jul. 31 at 1:13 PM
$ABBV staying long after 23yrs (original $39K to$3.2M w/periodic dip buying + reinvest).
3 · Reply
crtlabz
crtlabz Jul. 31 at 1:05 PM
$ABBV nothing wrong with these results
0 · Reply
Olivia_Strickland
Olivia_Strickland Jul. 31 at 12:52 PM
$ABBV got the EU approval headline overnight but premarket's down 5.6% at 248.20, tape feels heavy. Q2 earnings looming and someone's de-risking ahead of it. what level you guys watching here live premarket tape: https://tapeboard.com/go/st/research/ABBV?utm_source=stocktwits&utm_medium=post&utm_campaign=olivia&utm_content=abbv-pm-dn-tape&utm_term=research
0 · Reply
HydrogenH2
HydrogenH2 Jul. 31 at 12:40 PM
$ABBV Better entry point @ $225 !!
0 · Reply
fxshea
fxshea Jul. 31 at 12:36 PM
$ABBV Profit taking?
0 · Reply
shoagh12
shoagh12 Jul. 31 at 12:08 PM
$ABBV we wil change to Green Today Top Results
0 · Reply
grnstock
grnstock Jul. 31 at 12:02 PM
$ABBV I do not understand where 14 cents in the headline come from. Should it be 4 cents! GL
0 · Reply
profit_guru
profit_guru Jul. 31 at 11:59 AM
$ABBV - P/E too high…should be below 230 looks like its blockbuster drugs are showing slowdown…guidance weak
0 · Reply
grnstock
grnstock Jul. 31 at 11:58 AM
$ABBV great Q2 earnings, updated 2026 adj. eps guidance from $13.91 - $14.11 to $ $13.87 -$14.07 on Apogee buy. GL
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Jul. 31 at 11:56 AM
$ABBV Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $2.03 up 290.38% YoY • Reported revenue of $16.99B up 10.16% YoY • AbbVie is updating its 2026 adjusted diluted EPS guidance range from $13.91 - $14.11 to $13.87 - $14.07, reflecting an anticipated $0.14 dilutive impact from the proposed acquisition of Apogee Therapeutics.
0 · Reply